Any feedback?
Literature summary for 1.5.1.3 extracted from
- Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma (2008), Ann. Oncol., 19, 1500-1508.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | in clinical samples, a worse outcome is associated with increased levels of dihydrofolate reductase and C-MYC at diagnosis in osteosarcoma patients treated with a methotrexate-based protocol and of C-MYC in patients treated with a standard four-drug regimen. The assessment of C-MYC and dihydrolfolate reductase at diagnosis, together with that of other known prognostic markers, can be considered for an early identification of subgroups of OS patients with higher risk of adverse outcome | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
patients with osteosarcoma | - |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
